Ixekizumab Curbs Disease Activity, Improves Quality of Life in Axial Spondyloarthritis Ixekizumab Curbs Disease Activity, Improves Quality of Life in Axial Spondyloarthritis

Treatment with the interleukin-17 inhibitor ixekizumab (Taltz, Lilly) significantly improves signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA), according to results of the COAST-X study.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news